C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
Angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, are provided. The conditions include cancer, obesity, conditions associated with obesity, and neurodegenerative diseases such as general dementia, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, traumatic brain injury and spinal cord trauma..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Europäisches Patentamt - (2015) vom: 30. Juni Zur Gesamtaufnahme - year:2015 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
HARDING JOSEPH W [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2015-06-30, Last update posted on www.tib.eu: 2022-06-09, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
US9066901 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA007569580 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA007569580 | ||
| 003 | DE-627 | ||
| 005 | 20230504075247.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2015 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA007569580 | ||
| 035 | |a (EPA)US9066901 | ||
| 035 | |a (EPA)47556183 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a HARDING JOSEPH W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a C-Met receptor regulation by angiotensin IV (AT4) receptor ligands |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2015-06-30, Last update posted on www.tib.eu: 2022-06-09, Last updated: 2023-02-09 | ||
| 520 | |a Angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, are provided. The conditions include cancer, obesity, conditions associated with obesity, and neurodegenerative diseases such as general dementia, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, traumatic brain injury and spinal cord trauma. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a WRIGHT JOHN W |4 aut | |
| 700 | 0 | |a ELIAS PATRICK D |4 aut | |
| 700 | 0 | |a YAMAMOTO BRENT J |4 aut | |
| 700 | 0 | |a KAWAS LEEN H |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2015) vom: 30. Juni |
| 773 | 1 | 8 | |g year:2015 |g day:30 |g month:06 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/47556183/publication/US9066901A1?q=US9066901 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2015 |b 30 |c 06 |
| 951 | |a AR | ||
| 952 | |j 2015 |b 30 |c 06 | ||